SecBot SecBot
PRESS-RELEASE ·Filed Apr 9, 2026

IVVD

Invivyd
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

Traders should monitor enrollment and event accumulation rates in the DECLARATION study, as well as regulatory interactions for VMS063. The delay in VYD2311 results reduces near-term catalyst visibility, while VMS063 represents a high-risk, high-reward pipeline expansion into a new indication.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.78
T+0 close · Apr 9, 2026 · via day close
Latest settled
−53.15%
T+60 · $0.8340
Vs SPY
−63.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $1.78entry
  2. T+1 · 7mo ago −1.12%α −1.06% · $1.76
  3. T+5 · 7mo ago −3.93%α −7.12% · $1.71
  4. T+20 · 6mo ago −17.98%α −25.55% · $1.46
  5. T+60 · 4mo ago −53.15%α −63.93% · $0.8340
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invivyd announced progress in its Phase 3 DECLARATION study for VYD2311, including a pre-specified upsizing by ~500 subjects to ensure robust statistical power, pushing top-line results to Q3 2026. The company also announced the advancement of VMS063, a novel measles monoclonal antibody candidate, with IND readiness targeted for late 2026.

Key Facts

  • DECLARATION Phase 3 study upsized by ~500 subjects, increasing total enrollment beyond initial 1,818.
  • Top-line results for VYD2311 now expected in Q3 2026, a two-month delay from prior 'mid-year' guidance.
  • FDA alignment on initial Pediatric Study Plan (DRUMMER trial) for VYD2311 in children aged 0-11, contingent on adult trial success.
  • VMS063, a novel measles mAb candidate, advanced toward IND-enabling studies with target IND readiness in late 2026.
  • No clinical efficacy or safety data reported for either VYD2311 or VMS063; all updates are developmental and forward-looking.

Financial Impact

No immediate financial impact disclosed; long-term value hinges on successful development and regulatory approval of VYD2311 and VMS063.

revenueepsdilution

Risk Factors

  • Delayed timeline for VYD2311 results increases uncertainty and extends cash runway needs.
  • VMS063 is in early development with no clinical data; high risk of failure in later stages.
  • Forward-looking statements dominate; lack of concrete data limits near-term upside.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3270803

Track record

19 reports on IVVD

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
  2. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
  3. Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
  5. Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
  6. Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
  7. Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
  8. Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
  10. Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026